宅男视频

XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Menu

Haematology - Lymphoma & CLL Trials

A LIST OF OUR EARLY PHASE Haematology (Lymphoma & CLL)听TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the UCLH Find a Study database.

听

ALLCAR19

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Local Project Reference:
Principal Investigator:Dr Claire Roddie
Drug Class/ Treatrment:

CAR T-Cell Therapy

Expressing CD19 Chimeric Antigen Receptor (CD19CAR)

Patient Population:
  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
  • Chronic Lymphocytic Leukaemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Adults听>/=16 years old

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

NAVAL-1

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

Local Project Reference:
Principal Investigator:Dr. Kirit Ardeshna
Drug Class/ Treatrment:Nanatinostat听(Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication)
Patient Population:Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

听

On hold to recruitment

CO43805
A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA

Local Project Reference:
Principal Investigator:Dr WIlliam Townsend
Drug Class/Treatment:

Mosunetuzumab听(bispecific CD20-directed CD3 T-cell engager) or听Glofitamab听(CD20- and CD3- Bispecific Antibody)

In Combination with听CC-220听(cereblon E3 ligase modulator) + CC-99282听(E3 Ligase Modulator)

Patient Population:B-Cell Non-Hodgkin Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

听

Principal Investigator(s):

William Townsend Profile
Dr. william townsend

Consultant Haematologist